At Cyrano Therapeutics, we’re dedicated to developing therapies for people dealing with long-term loss of smell and taste. Prior to the COVID-19 pandemic, this condition affected over 15 million people in the U.S., with about 4 million cases resulting from flu viruses. Since COVID-19, however, the prevalence has increased over tenfold, with thousands of new cases emerging daily. This surge highlights the urgent need for effective treatments, and we’re committed to advancing solutions that restore these essential senses and enhance quality of life for those impacted.

This study is a 32-week, randomized, double-blinded, placebo-controlled trial evaluating the safety and effectiveness of CYR-064 as a potential treatment for hyposmia, the partial loss of smell. Beginning with a 4-week screening period to confirm participant eligibility, the trial aims to contribute valuable insights into the treatment of smell disorders by rigorously testing CYR-064’s impact on restoring olfactory function.

Olfactory dysfunction, or the loss or impairment of the sense of smell, affects millions worldwide. This condition, often caused by viral infections, head trauma, or neurodegenerative diseases, impacts more than just the ability to detect scents; it can significantly affect quality of life, safety, and mental health. People with olfactory dysfunction may struggle with food enjoyment, recognizing hazards like gas leaks or smoke, and even social interactions. Research and treatment advancements, such as those by Cyrano Therapeutics, aim to restore this essential sensory function.

Cyrano Therapeutics is a private, venture-backed clinical stage regenerative medicine company. Since our foundation, we have been working diligently to develop a therapy for people struggling with the loss of smell and flavor.

Our mission is to push the boundaries of medical science, bringing hope and healing to patients suffering from anosmia through advanced and effective smell loss therapy & treatments. With a team of world-class researchers and clinicians, Cyrano Therapeutics is at the forefront of smell loss therapy research and development, committed to delivering breakthroughs that matter.

We understand the profound impact that smell loss can have on quality of life. That’s why our dedicated research team is focused on creating therapies that restore this essential sense. By combining cutting-edge technology with compassionate care, we aim to offer patients a pathway to recovery and a renewed sense of smell.

At Cyrano Therapeutics, we believe in the power of science to change lives. Our ongoing commitment to innovation ensures that we remain leaders in the field of smell loss therapy, constantly seeking new ways to enhance patient outcomes and improve overall well-being.